Shanghai Medicilon Inc. (SHA:688202)

China · Delayed Price · Currency is CNY

56.99

+3.44 (6.42%)

At close: Jun 18, 2026

64.85% (1Y)

Market Cap	7.50B +83.8%
Revenue (ttm)	1.26B +20.6%
Net Income	-137.67M
EPS	-1.05
Shares Out	131.55M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,827,914
Open	53.85
Previous Close	53.55
Day's Range	52.80 - 58.38
52-Week Range	32.15 - 84.70
Beta	0.76
Analysts	Buy
Price Target	36.22 (-36.44%)
Earnings Date	Aug 20, 2026

About Shanghai Medicilon

Shanghai Medicilon Inc., a contract research organization, provides drug discovery and development services to pharmaceutical and biotechnology companies in China and internationally. The company operates in Drug Discovery and Pharmaceutical Research, and Preclinical Research segments. It offers medicinal and analytical chemistry; process development; custom and zoom in synthesis; structural, in vitro, and computational biology; protein expression and purification; protein crystallization; and recombinant kinase preparation services, as well as... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2004

Employees 2,504

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688202

Full Company Profile

Financial Performance

In 2025, Shanghai Medicilon's revenue was 1.16 billion, an increase of 12.08% compared to the previous year's 1.04 billion. Losses were -167.83 million, -49.27% less than in 2024.

Financial Statements